Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Not All Patients with Mild Phenotype of Gaucher Disease (GD) Need Disease Specific Treatment As Reflected By Patients Reported Outcomes Measures

Shoshana Revel-Vilk, MD, Tama Dinur, PhD, Majdolen Istaiti, Dafna Frydman, DMV, Michal Becker-Cohen, MSc, Ari Zimran, MD

Blood (2019) 134 (Supplement_1): 4712.

https://doi.org/10.1182/blood-2019-123000

Published: 2019

Journal Articles

Bone Marrow Involvement in Patients with Type 1 Gaucher Disease Receiving Low-Dose Long Term Enzyme Replacement Therapy (median 18 years)

Shoshana Revel-Vilk, MD, Jeffrey Szer, MBBS, Michal Becker Cohen, Ari Zimran, MD

Blood (2019) 134 (Supplement_1): 4862.

https://doi.org/10.1182/blood-2019-131013

Published: 2019

Journal Articles

Open-Label, Expanded Access Study of Taliglucerase Alfa in Patients with Gaucher Disease Requiring Enzyme Replacement Therapy

David J. Kuter, MD DPhil, Michael Wajnrajch, MD MPA, Betina Hernandez, MD, Rong Wang, MPH, Raul Chertkoff, MD MBA, Ari Zimran, MD

Blood (2018) 132 (Supplement 1): 3755.

https://doi.org/10.1182/blood-2018-99-112660

Published: 2018

Journal Articles

Reduction in Intravenous Infusion Duration of Enzyme Replacement Therapy to Ten Minutes with Velaglucerase Alfa in Adult Patients with Type 1 Gaucher Disease

Ari Zimran, MD, Shoshana Revel-Vilk, MD, Deborah Elstein, PhD, Naama Arbel, Michal Becker-Cohen, MSc, Gaya Chicco, Jeff Szer, MB, BS, FRACP

Blood (2017) 130 (Supplement 1): 2101.

https://doi.org/10.1182/blood.V130.Suppl_1.2101.2101

Published: 2017

Journal Articles

Eliglustat, an Investigational Oral Therapy for Gaucher Disease Type 1: Phase 2 Results After 4 Years of Treatment

M. Judith Peterschmitt, MD, Elena Lukina, PhD, MD, Nora Watman, MD, Marta Dragosky, M.D., Gregory M Pastores, Elsa Avila Arreguin, M.D., Hanna Rosenbaum, MD, Ari Zimran, MD, Elena Sysoeva, Rasha Aguzzi, Leorah H Ross, Ana Cristina Puga, M.D.

Blood (2012) 120 (21): 1038.

https://doi.org/10.1182/blood.V120.21.1038.1038

Published: 2012

Journal Articles

Preimplantation Genetic Diagnosis for Benign Hematological Disorders Combined with HLA Matching and Stem Cells Development.

Gheona Altarescu, Deborah Elstein, Ari Zimran, MD, Talia Eldar Geva, Ephrat Levy Lahad, Paul Renbaum

Blood (2012) 120 (21): 3167.

https://doi.org/10.1182/blood.V120.21.3167.3167

Published: 2012

Journal Articles

A Multicenter, Double-Blind, Randomized Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Patients with Gaucher Disease.

Ari Zimran, MD, Derlis Emilio Gonzalez-Rodriguez, MD, Aya Abrahamov, MD, Deborah Elstein, PhD, Rene Heitner, MD, Alona Paz, MD, Einat Brill-Almon, PhD, Raul Chertkoff, MD

Blood (2012) 120 (21): 2140.

https://doi.org/10.1182/blood.V120.21.2140.2140

Published: 2012

Journal Articles

Miglustat Therapy in Type 1 Gaucher Disease: Long-Term Treatment Experience From a Multicenter, Retrospective Cohort Study,

David J. Kuter, MD, DPhil, Atul Mehta, MD, Carla Hollak, MD, PhD, Pilar Giraldo, MD, PhD, Derralynn Hughes, MRCP, MRCPath, DPhil, MA, Nadia Belmatoug, MD, Monika Brand, Audrey Muller, Berthold Schaaf, Ruben Giorgino, Ari Zimran, MD

Blood (2011) 118 (21): 3207.

https://doi.org/10.1182/blood.V118.21.3207.3207

Published: 2011

Journal Articles

Gaucher Disease and LGL Proliferations: Provocative Commonality?

Rosa Ruchlemer, MD, Deborah Elstein, PhD, Eti Broide, Constantine Reinus, Hannah Maayaan, Ari Zimran, MD

Blood (2011) 118 (21): 1100.

https://doi.org/10.1182/blood.V118.21.1100.1100

Published: 2011

Journal Articles

Determinants of Persisting Thrombocytopenia In Patients with Type 1 Gaucher Disease Treated with Alglucerase/Imiglucerase for 4–5 Years

Maria D. Cappellini, MD, Nadia Belmatoug, Alex Cole, Stephan vom Dahl, Patrick Deegan, Jack Goldblatt, Barry E. Rosenbloom, MD, Anna Tylki-Szymañska, Neal J. Weinreb, MD, Ari Zimran, MD, Carla Hollak, MD, PhD

Blood (2010) 116 (21): 4719.

https://doi.org/10.1182/blood.V116.21.4719.4719

Published: 2010

Journal Articles

Platelet Adhesion Defect Is Common in Gaucher Disease.

Batia Roth, MD, Galia Ronen, MD, Dror Rosengarten, MD, Alexander Brill, MD,PhD, Shoshana Vilk, MD, Tony Futerman, PhD, Swetlana Boldin-Adamsky, PhD, Ari Zimran, MD, David Varon, MD

Blood (2006) 108 (11): 1105.

https://doi.org/10.1182/blood.V108.11.1105.1105

Published: 2006

Journal Articles

Effect of Enzyme Replacement Therapy on Bone Mineral Density in Type 1 Gaucher Disease.

Richard Wenstrup, MD, Katherine Kacena, PhD, Paige Kaplan, MD, Gregory Pastores, MD, Ainu Prakash-Cheng, PhD, MD, Ari Zimran, MD, Thomas Hangartner, PhD

Blood (2005) 106 (11): 3895.

https://doi.org/10.1182/blood.V106.11.3895.3895

Published: 2005

Journal Articles

Phase I/II, Nine Month Study Results of Enzyme Replacement Therapy with Gene Activated Human Glucocerebrosidase (GA-GCB) in Patients with Type I Gaucher Disease.

Ari Zimran, MD, Candida Fratazzi, MD, Robert Mensah, PhD, Deborah Elstein, PhD

Blood (2005) 106 (11): 3882.

https://doi.org/10.1182/blood.V106.11.3882.3882

Published: 2005

NARROW

Not All Patients with Mild Phenotype of Gaucher Disease (GD) Need Disease Specific Treatment As Reflected By Patients Reported Outcomes Measures

Bone Marrow Involvement in Patients with Type 1 Gaucher Disease Receiving Low-Dose Long Term Enzyme Replacement Therapy (median 18 years)

Open-Label, Expanded Access Study of Taliglucerase Alfa in Patients with Gaucher Disease Requiring Enzyme Replacement Therapy

Reduction in Intravenous Infusion Duration of Enzyme Replacement Therapy to Ten Minutes with Velaglucerase Alfa in Adult Patients with Type 1 Gaucher Disease

Eliglustat, an Investigational Oral Therapy for Gaucher Disease Type 1: Phase 2 Results After 4 Years of Treatment

Preimplantation Genetic Diagnosis for Benign Hematological Disorders Combined with HLA Matching and Stem Cells Development.

A Multicenter, Double-Blind, Randomized Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Patients with Gaucher Disease.

Miglustat Therapy in Type 1 Gaucher Disease: Long-Term Treatment Experience From a Multicenter, Retrospective Cohort Study,

Gaucher Disease and LGL Proliferations: Provocative Commonality?

Determinants of Persisting Thrombocytopenia In Patients with Type 1 Gaucher Disease Treated with Alglucerase/Imiglucerase for 4–5 Years

Platelet Adhesion Defect Is Common in Gaucher Disease.

Effect of Enzyme Replacement Therapy on Bone Mineral Density in Type 1 Gaucher Disease.

Phase I/II, Nine Month Study Results of Enzyme Replacement Therapy with Gene Activated Human Glucocerebrosidase (GA-GCB) in Patients with Type I Gaucher Disease.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only